Identification of a JAK2 mutation in Polycythemia Vera

Details Identification of a JAK2 mutation in Polycythemia Vera Identification of a JAK2 mutation in Polycythemia Vera

2007-11-02

2008-09-30

Bausch, Sarae (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S024300, C435S091200

Reexamination Certificate

active

07429456

ABSTRACT:
The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

REFERENCES:
patent: 5914393 (1999-06-01), Coleman
patent: WO-95-11995 (1995-04-01), None
Kralovics et al ( New England Journal of Medicine (2005) vol. 352, pp. 1779-1790).
JAK2 GeneCard (genecards.org/cgi-bin/carddisp.pl?gene=JAK2&search=jak2&suff=txt, Dec. 27, 2007, pp. 1-17).
Rossi et al ( Leukeimai Research (2007) vol. 31, pp. 97-101).
Teffen et al (Leukemia Research (2006) vol. 30, pp. 739-744).
Kiladjian, J. et al. “Analysis of JAK2 Mutation in Essential Thrombocythemia (ET) Patients with Monoclonal and Polyclonal X-Chromosome Inactivation Patterns (XCIPs)”Blood(ASH 47-Annual Meeting Abstract) 106: Abstract # 2603 Nov. 2005.
Fiorini, A. et al. “Clonality Assay (X-CIP) and Jak2 V617P Mutation: Clustering Patients with Essential Thrombocythemia at High Risk for Thrombosis”Blood(ASH 47—Annual Meeting Abstract) 106: Abstract # 2597 Nov. 2005.
Finazzi, G. et al. “JAKVal617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia”Blood(ASH 47-Annual Meeting Abstract) 106: Abstract # 2580 Nov. 2005.
Tefferi, A. et al. “Concomitant Neutrophil JAK2V617F Mutation Screening and PRV-1 Expression Analysis in Myeloproliferative Disorders and Secondary Polycythaemia”British J. Hematology 131: 166-171 2005.
Chloe, James, et al., “A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera” Nature (London), vol. 434, No. 7037, Apr. 2005, pp. 1144-1148, XP002369147 ISSN: 0028-0836.
Baxter, E. J., et al., The Cancer Genome Project “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders” Lancet The, Lancet Limited. London, GB, vol. 365, No. 9464, Mar. 19, 2005, pp. 1054-1061, XP004798459 ISSN: 0140-6.
Ugo, V., et al:, “Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera” Experimental Hematology, New York, NY, US, vol. 32, No. 2, Feb. 2004, pp. 179-187, XP002324352 ISSN: 0301-472X.
Saltzmann, Alan, et al:, “Cloning and characterization of human Jak-2 kinase: High mRNA expression in immune cells and muscle tissue” Biochemical and Biophysical Research Communications, vol. 246, No. 3, May 29, 1998, pp. 627-633, XP002324351 ISSN: 0006-291X.
Pahl, H. L:, “Towards a Molecular Understanding of Polycythemia Rubra Vera” European Journal of Biochemistry, Berlin, Germany, vol. 267, No. 12, Jun. 2000, pp. 3395-3401, XP000982035 ISSN: 0014-2956.
Jones, A.V., et al., “Widespread Occurrence of the JAK2 V61F Mutation in chronic Myeloproliferative Disorders,” Blood (Washington, DC) 106 (6): 2162-12168 (2005).
Levine, R. L., et al., “Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia and Myeloid Metaplasia with Myelofibrosis,” Cancer Cell. 2005; 7: 387-397.
Kralovics, R., et al., “A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders,” N Engl J Med 2005; 352:1779-1790, Apr. 28, 2005.
Zhao R., Xing S., Li Z., et al., Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788-92.
PCT/EP2005/055586, An International Search Report/Written Opinion (English Translation).
FR 200411480, Inpadoc report (Jul. 25, 2007).
FR 200411480, Derwent report (Jul. 25, 2007).
Database UniProt [Online] Jun. 7, 2005, “Janus kinase 2.” XP002369149 extrait de EBI accession No. UNIPROT:Q506Q0 Database accession No. Q506Q0 Plus Commercial Vendor Search of (Seq ID Nos. 1 and 3-12) summarized in a chart which contains a list of the alignments from DGENE, USGENE and Registry (PCTGEN and NCBI contained no unique results), by the STN accession number, the homology score, the assignee/corporate source, the title of the patent/article, the patent number/journal information, and the publication date.

Affiliated with

Also associated with

Rating

Identification of a JAK2 mutation in Polycythemia Vera does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Identification of a JAK2 mutation in Polycythemia Vera, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identification of a JAK2 mutation in Polycythemia Vera will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3970702